KIM PETER S

Average Profitability
<0.0001%
Insider Buys Quantity
11
Insider Buys Sum
$641,939.18
Insider Sells Quantity
1
Insider Sells Sum
$38.22M

Insider Activity of KIM PETER S

According to the SEC Form 4 filings, KIM PETER S, being in a position of

  1. director at Entrada Therapeutics, Inc.,
    оver the last 12 months, has bought 45368 shares for $641,939, and sold 0 shares,
    over all time since 2024-03-19, has bought 45368 shares for $641,939, and sold 0 shares.

The largest purchase of all time was on 2024-05-14 and amounted to 25000 shares of Entrada Therapeutics, Inc. for $364,673.

The largest sale of all time was on 2012-11-05 and amounted to 840000 shares of Merck & Co., Inc. for $38.22M.

Biography of KIM PETER S

No biography is available at this moment.

2024-05-14PurchaseEntrada Therapeutics, Inc.
TRDA
director
25,000
0.0761%
$14.59$364,673+11.5%
2024-05-09PurchaseEntrada Therapeutics, Inc.
TRDA
director
2,200
0.0065%
$14.25$31,341+9.96%
2024-05-08PurchaseEntrada Therapeutics, Inc.
TRDA
director
2,276
0.0068%
$14.04$31,965+12.31%
2024-04-08PurchaseEntrada Therapeutics, Inc.
TRDA
director
2,600
0.0078%
$13.57$35,290+14.94%
2024-03-28PurchaseEntrada Therapeutics, Inc.
TRDA
director
1,512
0.0044%
$13.75$20,794+7.34%
2024-03-26PurchaseEntrada Therapeutics, Inc.
TRDA
director
2,750
0.0082%
$13.64$37,509+9.96%
2024-03-25PurchaseEntrada Therapeutics, Inc.
TRDA
director
3,180
0.0095%
$13.36$42,472+13.04%
2024-03-22PurchaseEntrada Therapeutics, Inc.
TRDA
director
3,118
0.0094%
$13.76$42,901+9.79%
2024-03-21PurchaseEntrada Therapeutics, Inc.
TRDA
director
704
0.0021%
$13.24$9,318+10.97%
2024-03-20PurchaseEntrada Therapeutics, Inc.
TRDA
director
1,128
0.0032%
$12.66$14,281+12.51%
2024-03-19PurchaseEntrada Therapeutics, Inc.
TRDA
director
900
0.0027%
$12.66$11,397+18.19%
2012-11-05SaleMerck & Co., Inc.
MRK
Exe V-P & Pres, MRL
840,000
0.0277%
$45.50$38.22M+4.02%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.